Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRXRXRecursion Pharmaceuticals$5.59-2.3%$5.94$3.79▼$12.36$2.30B112.36 million shs14.86 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRXRXRecursion Pharmaceuticals-2.27%+0.18%+5.67%-27.31%-28.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRXRXRecursion Pharmaceuticals2.2177 of 5 stars3.22.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRXRXRecursion Pharmaceuticals 2.33Hold$8.2046.69% UpsideCurrent Analyst Ratings BreakdownLatest RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.004/8/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.002/28/2025RXRXRecursion PharmaceuticalsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/28/2025RXRXRecursion PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$7.00 ➝ $6.002/6/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRXRXRecursion Pharmaceuticals$58.49M38.42N/AN/A$1.98 per share2.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRXRXRecursion Pharmaceuticals-$328.07M-$1.66N/AN/AN/A-579.52%-76.56%-55.68%5/5/2025 (Estimated)Latest RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025RXRXRecursion Pharmaceuticals-$0.44N/AN/AN/A$18.12 millionN/A2/28/2025Q4 2024RXRXRecursion Pharmaceuticals-$0.36-$0.53-$0.17-$0.53$19.04 million$4.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRXRXRecursion Pharmaceuticals0.044.354.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipRXRXRecursion Pharmaceuticals15.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRXRXRecursion Pharmaceuticals400401.99 million329.18 millionOptionableRXRX HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.8% Higher - Should You Buy?April 30 at 3:36 PM | marketbeat.comWas Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?April 29 at 10:20 AM | finance.yahoo.comBarclays PLC Has $4.28 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 29 at 3:51 AM | marketbeat.comRecursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth KnowingApril 28 at 6:55 PM | zacks.comRecursion to Report First Quarter 2025 Business Updates and Financial Results on May 5thApril 28 at 8:27 AM | globenewswire.combluebird bio (NASDAQ:BLUE) and Recursion Pharmaceuticals (NASDAQ:RXRX) Critical AnalysisApril 27, 2025 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 1.3% Higher - Should You Buy?April 26, 2025 | marketbeat.comLegal & General Group Plc Raises Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 26, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1.9% - Still a Buy?April 25, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 5.5% - What's Next?April 24, 2025 | marketbeat.comWells Fargo & Company MN Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 24, 2025 | marketbeat.comRecursion to present clinical data from ongoing Phase 1b/2 trial of REC-4881April 24, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 3.2% - Time to Buy?April 23, 2025 | marketbeat.com3 Monster Stocks to Hold for the Next 10 YearsApril 23, 2025 | fool.comRecursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025April 22, 2025 | globenewswire.comRecursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should KnowApril 21, 2025 | msn.comWhich Is a Better Investment, Alvotech or Recursion Pharmaceuticals, Inc. Stock?April 21, 2025 | aaii.comRockefeller Capital Management L.P. Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 21, 2025 | marketbeat.comNan Fung Group Holdings Ltd Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 20, 2025 | marketbeat.comInvestment strategist picks 3 ‘new age' healthcare stocks to buyApril 20, 2025 | finbold.comXTX Topco Ltd Invests $565,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRXRX Company DescriptionsRecursion Pharmaceuticals NASDAQ:RXRX$5.59 -0.13 (-2.27%) As of 04/30/2025 04:00 PM EasternRecursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
